.

Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Deloitte
Cipla
QuintilesIMS
Citi
Johnson and Johnson
Harvard Business School
AstraZeneca
Covington
US Department of Justice

Generated: November 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,058,267

« Back to Dashboard

Which drugs does patent 8,058,267 protect, and when does it expire?


Patent 8,058,267 protects OCALIVA and is included in one NDA.

This patent has fourteen patent family members in eleven countries.

Summary for Patent: 8,058,267

Title:Steroids as agonists for FXR
Abstract: The invention relates to compounds of formula (I): ##STR00001## wherein R is ethyl and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof. The compounds of formula (I) are useful as FXR agonists.
Inventor(s): Pellicciari; Roberto (Perugia, IT)
Assignee: Intercept Pharmaceuticals, Inc. (New York, NY)
Application Number:12/547,147
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Intercept Pharms Inc
OCALIVA
obeticholic acid
TABLET;ORAL207999-001May 27, 2016RXYesNo► Subscribe► Subscribe TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC)
Intercept Pharms Inc
OCALIVA
obeticholic acid
TABLET;ORAL207999-002May 27, 2016RXYesYes► Subscribe► Subscribe TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC)
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,058,267

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,138,390Steroids as agonists for FXR► Subscribe
8,969,330Steroids as agonists for FXR► Subscribe
9,732,117Steroids as agonists for FXR► Subscribe
8,377,916Steroids as agonists for FXR► Subscribe
7,786,102Steroids as agonists for FXR► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,058,267

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Norway2017022► Subscribe
Norway326134► Subscribe
Norway20034011► Subscribe
Japan2007269815► Subscribe
Japan4021327► Subscribe
Japan2004519492► Subscribe
Israel157816► Subscribe
Spain2248581► Subscribe
European Patent Office1392714► Subscribe300877Netherlands► Subscribe
European Patent Office1392714► SubscribeCA 2017 00025Denmark► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Express Scripts
Daiichi Sankyo
Teva
Covington
Boehringer Ingelheim
Merck
Mallinckrodt
Dow
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot